News

benzinga_article
2025.12.03 17:03
Crinetics Pharmaceuticals shares are trading higher after the company announced it does its first patient n the Phase 1/2 study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2-positive neuroendocrine tumors and other SST2-expressing solid tumors.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer